A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild-Type Patients With (i) Advanced Triple-Negative Breast Cancer and Homologous Recombination Deficiency, and (ii) Advanced HER2-Negative Breast Cancer or Other Solid Tumors With Either a Mutation in Homologous Recombination Pathway Genes

Trial Profile

A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild-Type Patients With (i) Advanced Triple-Negative Breast Cancer and Homologous Recombination Deficiency, and (ii) Advanced HER2-Negative Breast Cancer or Other Solid Tumors With Either a Mutation in Homologous Recombination Pathway Genes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Advanced breast cancer; Male breast cancer; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 12 Dec 2015 Trial design presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 10 Aug 2015 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top